Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3466 AL 3480

Advanced analytical methodologies in Alzheimer's disease drug discovery

De Simone A, Naldi M, Tedesco D, Bartolini M, Davani L, Andrisano V.

J Pharm Biomed Anal. 2020 Jan 30;178:112899. doi: 10.1016/j.jpba.2019.112899. Epub 2019 Sep 29.

The Structure and Function of α, β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review

Ahmad SS, Khan S, Kamal MA, Wasi U.

CNS Neurol Disord Drug Targets. 2019;18(9):657-667. doi: 10.2174/1871527318666191011145941.

Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease

Naushad M, Durairajan SSK, Bera AK, Senapati S, Li M.

Planta Med. 2019 Nov;85(17):1316-1325. doi: 10.1055/a-1019-9819. Epub 2019 Oct 16.

Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease

Dubey T, Chinnathambi S.

Arch Biochem Biophys. 2019 Nov 15;676:108153. doi: 10.1016/j.abb.2019.108153. Epub 2019 Oct 14.

Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease

Chan HH, Koh RY, Lim CL, Leong CO.

Curr Alzheimer Res. 2019;16(10):907-918. doi: 10.2174/1567205016666191023102422.

Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches

Tibbo AJ, Tejeda GS, Baillie GS.

Biochem Soc Trans. 2019 Oct 31;47(5):1557-1565. doi: 10.1042/BST20190763.

Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease

Vander Zanden CM, Chi EY.

J Pharm Sci. 2020 Jan;109(1):68-73. doi: 10.1016/j.xphs.2019.10.024. Epub 2019 Oct 21.

Tubulin: Structure, Functions and Roles in Disease

Binarová P, Tuszynski J.

Cells. 2019 Oct 22;8(10):1294. doi: 10.3390/cells8101294.

Investigational BACE inhibitors for the treatment of Alzheimer's disease

Imbimbo BP, Watling M.

Expert Opin Investig Drugs. 2019 Nov;28(11):967-975. doi: 10.1080/13543784.2019.1683160. Epub 2019 Oct 29.

Considerations for future tau-targeted therapeutics: can they deliver?

Noble W, Jimenez-Sanchez M, Perez-Nievas BG, Hanger DP.

Expert Opin Drug Discov. 2020 Mar;15(3):265-267. doi: 10.1080/17460441.2020.1685977. Epub 2019 Oct 29.

Editorial: Can Digital Technology Advance the Development of Treatments for Alzheimer's Disease?

Mc Carthy M, Schueler P.

J Prev Alzheimers Dis. 2019;6(4):217-220. doi: 10.14283/jpad.2019.32.

Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer's Disease

McLarnon JG.

Curr Alzheimer Res. 2019;16(11):1007-1017. doi: 10.2174/1567205016666191106095038.

Alzheimer's therapy development: A few points to consider

Sigurdsson EM.

Prog Mol Biol Transl Sci. 2019;168:205-217. doi: 10.1016/bs.pmbts.2019.06.001. Epub 2019 Jun 26.

Why delay in effective treatment for Alzheimer's disease and related conditions

Iqbal K, Liu F, Gong C, Dai C, Hu W.

Prog Mol Biol Transl Sci. 2019;168:243-256. doi: 10.1016/bs.pmbts.2019.08.002. Epub 2019 Aug 30.

Carotenoids as Novel Therapeutic Molecules Against Neurodegenerative Disorders: Chemistry and Molecular Docking Analysis

Lakey-Beitia J, Kumar D J, Hegde ML, Rao KS.

Int J Mol Sci. 2019 Nov 7;20(22):5553. doi: 10.3390/ijms20225553.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias